Carboplatin/Paclitaxel
Phase 3Small molecule
AstraZenecaCarboplatin/Paclitaxel is one of 46 small molecule programs targeting Penile Cancer. It is currently in Phase 3.
2
Indications
9
Total Trials
4
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
449 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Sacituzumab Tirumotecan
Merck & Co.Phase 3
SYS6010
CCSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 3
Ds-1062a
Daiichi SankyoPhase 3
Carboplatin/Paclitaxel
AstraZenecaPhase 3
Remeron
OOrganon and Co
Preclinical
Valemetostat Tosylate
Daiichi SankyoPreclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer3 trials
Carboplatin1 trial
Penile Cancer1 trial
Esophageal Cancer1 trial
Ovarian Cancer1 trial
Comparison of Weekly Versus Every Three Weeks of Carboplatin Plus Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer
Completed·—·Phase 1/2·NCT05963334·49 enrolled
2 more indications
Melanoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Carboplatin/Paclitaxel. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company